VIIBRYD Drug Patent Profile
✉ Email this page to a colleague
When do Viibryd patents expire, and when can generic versions of Viibryd launch?
Viibryd is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Viibryd
A generic version of VIIBRYD was approved as vilazodone hydrochloride by TEVA PHARMS USA on September 30th, 2019.
Summary for VIIBRYD
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 85 |
Clinical Trials: | 16 |
Patent Applications: | 500 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIIBRYD |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIIBRYD |
What excipients (inactive ingredients) are in VIIBRYD? | VIIBRYD excipients list |
DailyMed Link: | VIIBRYD at DailyMed |
Recent Clinical Trials for VIIBRYD
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Forest Laboratories | Phase 1 |
New York State Psychiatric Institute | Phase 4 |
Forest Laboratories | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for VIIBRYD
Paragraph IV (Patent) Challenges for VIIBRYD
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VIIBRYD | Tablets | vilazodone hydrochloride | 10 mg, 20 mg, and 40 mg | 022567 | 5 | 2015-01-21 |
US Patents and Regulatory Information for VIIBRYD
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIIBRYD
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIIBRYD
See the table below for patents covering VIIBRYD around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1109447 | ⤷ Sign Up | |
Slovakia | 281793 | ⤷ Sign Up | |
Canada | 2782868 | ⤷ Sign Up | |
Ukraine | 76758 | ПОЛИМОРФНЫЕ ФОРМЫ ГИДРОХЛОРИДА 1-[4-(5-ЦИАНОИНДОЛ-3-ИЛ)БУТИЛ]-4-(2-КАРБАМОИЛБЕНЗОФУРАН-5-ИЛ)-ПИПЕРАЗИНА;ПОЛІМОРФНІ ФОРМИ ГІДРОХЛОРИДУ 1-'4-(5-ЦІАНОІНДОЛ-3-ІЛ)БУТИЛ-4-(2-КАРБАМОЇЛБЕНЗОФУРАН-5-ІЛ)ПІПЕРАЗИНУ (POLYMORPH FORMS OF HYDROCHLORIDE OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYL-BENZOFURAN-5-YL)-PIPERAZINE) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |